barzolvolimab
Monoclonal antibody
Evidence outlook · lead readout
EMBARQ-CSU1 (NCT06445023) · Chronic Spontaneous Urticaria
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
EMBARQ-CSU1 (NCT06445023): This was a randomized, double-blind, placebo-controlled Phase 3 in chronic spontaneous urticaria. Its primary endpoint, UAS7 change at week 12, is a validated clinical scale and was met according to the company's topline release. The sources read give no power calculation, so the grade is moderate.
Also in development:Atopic Dermatitis · Phase 2Chronic Inducible Urticaria · Phase 3
Development in Eosinophilic Esophagitis stopped (2025-08) after a negative readout. Source
Development in Prurigo Nodularis stopped (2026-07) after a negative readout. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
EMBARQ-CSU2 NCT06455202 · Chronic Spontaneous Urticaria This was a randomized, double-blind, placebo-controlled Phase 3 in chronic spontaneous urticaria. Its primary endpoint, UAS7 change at week 12, is a validated clinical scale and was met according to the company's topline release. The sources read give no power calculation, so the grade is moderate. Registry: NCT06455202 | 3 | Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score) (From Day 1 (first dose) to Day 85 (Week 12)) 2026-08-04 | Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22). | Partial signal | link ↗ |
View 1 more trial
EMBARQ-CSU1 NCT06445023 · Chronic Spontaneous Urticaria This was a randomized, double-blind, placebo-controlled Phase 3 in chronic spontaneous urticaria. Its primary endpoint, UAS7 change at week 12, is a validated clinical scale and was met according to the company's topline release. The sources read give no power calculation, so the grade is moderate. Registry: NCT06445023 | 3 | Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score) (From Day 1 (first dose) to Day 85 (Week 12)) 2026-08-12 | Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other KIT drugs
bezuclastinib, Velzatinib, Briquilimab, SAR449028. Compare all 5 KIT drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Chronic Spontaneous Urticaria: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Barzolvolimab: this drug | Phase 3 | Monoclonal antibody | KIT | Partial signal | NCT06445023: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22). NCT06455202: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22). | |
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Omalizumab (Xolair) | Approved | Monoclonal antibody | IgE (immunoglobulin E), IgE | Partial signal | NCT01287117: Change From Baseline to Week 12 in the Weekly Itch Severity Score (Baseline to Week 12): Placebo -3.63 Units on a scale (Standard Deviation 5.22) | Omalizumab 75 mg -6.46 Units on a scale (Standard Deviation 6.14) | Omalizumab 150 mg -6.66 Units on a scale (Standard Deviation 6.28) | Omalizumab 300 mg -9.4 Units on a scale (Standard Deviation 5.73) NCT01292473: Change in weekly itch severity score at week 12 vs placebo (-5.14): omalizumab 75 mg -5.87, difference -0.69 (95% CI -2.54 to 1.16), p=0.4637; 150 mg -8.14, difference -3.04 (95% CI -4.85 to -1.24), p=0.0011; 300 mg -9.77, difference -4.81 (95% CI -6.49 to -3.13), p<0.0001 (CT.gov posted results). | |
| Remibrutinib | Approved | Small molecule | Bruton's tyrosine kinase (BTK) | Reliable signal | No reviewed efficacy summary in this indication | |
| Bezuclastinib | Phase 3(overall) | Small molecule | KIT | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Velzatinib | Phase 3(overall) | Small molecule | KIT | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| AK139 | Phase 2 | Multispecific antibody | IL-4 receptor alpha / ST2 | not yet graded | No reviewed efficacy summary in this indication | |
| CM512 | Phase 2 | Multispecific antibody | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-3095 | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Briquilimab | Phase 1/2 | Monoclonal antibody | KIT | not yet graded | No reviewed efficacy summary in this indication | |
| Girocitinib | —(overall) | Small molecule | TYK2/JAK1 | Reliable signal | No reviewed efficacy summary in this indication | |
| SAR449028 | —(overall) | Undisclosed | KIT | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-3095 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow barzolvolimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent